Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
16 févr. 2023 16h44 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...